Cargando…

Serum levels of olfactomedin 4: a biomarker for asthma control state in asthmatics

BACKGROUND: Neutrophils are a key component of inflammation in asthma. Olfactomedin 4 (OLFM4) is produced by neutrophils and has been reported to be associated with asthma inflammation. We hypothesized that serum OLFM4 may be increased in asthmatic individuals and can assist with predicting asthma c...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xingyuan, Khalid, Khan, Chen, Dandan, Qiu, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210139/
https://www.ncbi.nlm.nih.gov/pubmed/32395538
http://dx.doi.org/10.21037/atm.2020.03.213
_version_ 1783531219503284224
author Chen, Xingyuan
Khalid, Khan
Chen, Dandan
Qiu, Chen
author_facet Chen, Xingyuan
Khalid, Khan
Chen, Dandan
Qiu, Chen
author_sort Chen, Xingyuan
collection PubMed
description BACKGROUND: Neutrophils are a key component of inflammation in asthma. Olfactomedin 4 (OLFM4) is produced by neutrophils and has been reported to be associated with asthma inflammation. We hypothesized that serum OLFM4 may be increased in asthmatic individuals and can assist with predicting asthma control state. METHODS: A total of 79 individuals were enrolled from Shenzhen People’s Hospital, China and divided into 3 groups: uncontrolled asthmatics (n=35), controlled asthmatics (n=14), and healthy controls (n=30). The serum OLFM4 level was measured by enzyme-linked immunosorbent assay (ELISA). Clinical characteristics (such as age, gender, allergy history, body mass index (BIM), and smoking history), clinical indicators (such as whole blood count, sputum neutrophil, sputum eosinophil, forced expiratory volume in one second as percentage of predicted volume (FEV1% pred), IgE level, high sensitivity C-reactive protein (hs-CRP), and fractional expiratory nitric oxide (FeNO) were measured and the three groups were compared. The correlation between OLFM4 and the clinical characteristics and indicators was then evaluated. Finally, stepwise multiple regression analysis was performed to determine the contribution of clinical characteristics and clinical indicators influencing serum OLFM4 level. RESULTS: Our results showed that the serum OLFM4 level was increased two-fold in the controlled asthma group (3,450.38±3,000.35 pg/mL) and three-fold in the uncontrolled asthma group (5,084.57±3,425.76 pg/mL), compared to the healthy control group (1,830.11±1,239.70 ng/mL) (P<0.001). We found a positive correlation between serum OLFM4 level and sputum neutrophils (P<0.001). OLFM4 was also found to be related to both hs-CRP level (P=0.007*) and blood neutrophil count (P<0.001). There were no significant associations identified between OLFM4 and age, gender, BMI, allergy, blood eosinophils, blood neutrophils, IgE, FeNO, or FEV1% pred. CONCLUSIONS: Serum OLFM4 levels were increased in patients with asthma (the controlled asthma and uncontrolled asthma groups). There was a significant correlation between serum OLFM4 and levels of sputum neutrophil and hs-CRP, and OLFM4 was also related to both Hs-CRP level and blood neutrophil count. Serum OLFM4 level may serve as a useful biomarker for assessing asthma control state in asthmatic adults.
format Online
Article
Text
id pubmed-7210139
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-72101392020-05-11 Serum levels of olfactomedin 4: a biomarker for asthma control state in asthmatics Chen, Xingyuan Khalid, Khan Chen, Dandan Qiu, Chen Ann Transl Med Original Article BACKGROUND: Neutrophils are a key component of inflammation in asthma. Olfactomedin 4 (OLFM4) is produced by neutrophils and has been reported to be associated with asthma inflammation. We hypothesized that serum OLFM4 may be increased in asthmatic individuals and can assist with predicting asthma control state. METHODS: A total of 79 individuals were enrolled from Shenzhen People’s Hospital, China and divided into 3 groups: uncontrolled asthmatics (n=35), controlled asthmatics (n=14), and healthy controls (n=30). The serum OLFM4 level was measured by enzyme-linked immunosorbent assay (ELISA). Clinical characteristics (such as age, gender, allergy history, body mass index (BIM), and smoking history), clinical indicators (such as whole blood count, sputum neutrophil, sputum eosinophil, forced expiratory volume in one second as percentage of predicted volume (FEV1% pred), IgE level, high sensitivity C-reactive protein (hs-CRP), and fractional expiratory nitric oxide (FeNO) were measured and the three groups were compared. The correlation between OLFM4 and the clinical characteristics and indicators was then evaluated. Finally, stepwise multiple regression analysis was performed to determine the contribution of clinical characteristics and clinical indicators influencing serum OLFM4 level. RESULTS: Our results showed that the serum OLFM4 level was increased two-fold in the controlled asthma group (3,450.38±3,000.35 pg/mL) and three-fold in the uncontrolled asthma group (5,084.57±3,425.76 pg/mL), compared to the healthy control group (1,830.11±1,239.70 ng/mL) (P<0.001). We found a positive correlation between serum OLFM4 level and sputum neutrophils (P<0.001). OLFM4 was also found to be related to both hs-CRP level (P=0.007*) and blood neutrophil count (P<0.001). There were no significant associations identified between OLFM4 and age, gender, BMI, allergy, blood eosinophils, blood neutrophils, IgE, FeNO, or FEV1% pred. CONCLUSIONS: Serum OLFM4 levels were increased in patients with asthma (the controlled asthma and uncontrolled asthma groups). There was a significant correlation between serum OLFM4 and levels of sputum neutrophil and hs-CRP, and OLFM4 was also related to both Hs-CRP level and blood neutrophil count. Serum OLFM4 level may serve as a useful biomarker for assessing asthma control state in asthmatic adults. AME Publishing Company 2020-04 /pmc/articles/PMC7210139/ /pubmed/32395538 http://dx.doi.org/10.21037/atm.2020.03.213 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Chen, Xingyuan
Khalid, Khan
Chen, Dandan
Qiu, Chen
Serum levels of olfactomedin 4: a biomarker for asthma control state in asthmatics
title Serum levels of olfactomedin 4: a biomarker for asthma control state in asthmatics
title_full Serum levels of olfactomedin 4: a biomarker for asthma control state in asthmatics
title_fullStr Serum levels of olfactomedin 4: a biomarker for asthma control state in asthmatics
title_full_unstemmed Serum levels of olfactomedin 4: a biomarker for asthma control state in asthmatics
title_short Serum levels of olfactomedin 4: a biomarker for asthma control state in asthmatics
title_sort serum levels of olfactomedin 4: a biomarker for asthma control state in asthmatics
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210139/
https://www.ncbi.nlm.nih.gov/pubmed/32395538
http://dx.doi.org/10.21037/atm.2020.03.213
work_keys_str_mv AT chenxingyuan serumlevelsofolfactomedin4abiomarkerforasthmacontrolstateinasthmatics
AT khalidkhan serumlevelsofolfactomedin4abiomarkerforasthmacontrolstateinasthmatics
AT chendandan serumlevelsofolfactomedin4abiomarkerforasthmacontrolstateinasthmatics
AT qiuchen serumlevelsofolfactomedin4abiomarkerforasthmacontrolstateinasthmatics